AbCellera Biologics (ABCL) Stock Analysis & AI Equity Report
AbCellera Biologics (ABCL) overview
AbCellera Biologics (ABCL) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 75.1m and operating profit of USD -217m; the year-end share price was 3.42 USD and market capitalisation was USD 1,028m. AbCellera Biologics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get AbCellera Biologics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About AbCellera Biologics
AbCellera discovers and develops antibody-based medicines through a platform combining experimental technology, data science, and drug development capabilities. Its programs span endocrinology, women’s health, immunology, and oncology. The company advances its own therapeutic candidates and collaborates with biotechnology and pharmaceutical partners on drug programs. Its pipeline includes ABCL635 for vasomotor symptoms and other investigational antibodies.
Generate the AbCellera Biologics report
AbCellera Biologics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for AbCellera Biologics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on AbCellera Biologics
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.